NEXTBIOMEDICAL's Resorbable Pain Solution Nexsphere-F™ Wins Health Canada Approval

By Matthew Richardson

SEOUL, South Korea – January 29, 2026 – In a significant development for millions suffering from chronic musculoskeletal pain, NEXTBIOMEDICAL CO., LTD. has secured approval from Health Canada for its innovative medical device, Nexsphere-F™. The decision opens the Canadian market to a novel treatment for conditions like osteoarthritis and marks a critical step in the South Korean company's strategy for North American expansion.

Nexsphere-F™ is a fast-resorbing microsphere used in a minimally invasive procedure called embolization. This approval positions the device as a promising new option for patients and clinicians seeking alternatives to conventional pain management, which often relies on drugs with side effects or more invasive surgical interventions.

A Resorbable Revolution in Pain Treatment

The core innovation of Nexsphere-F™ lies in its unique composition. The device consists of tiny, gelatin-based spheres that are injected into the bloodstream to block abnormal blood vessels that often develop around inflamed joints and tendons. These problematic vessels are associated with the generation of chronic pain signals. By temporarily cutting off their blood supply—a process known as embolization—the procedure induces the necrosis (death) of pain-generating nerve cells in the targeted area within hours.

What sets Nexsphere-F™ apart from other embolic agents is its transience. Unlike permanent microspheres that remain in the body indefinitely and carry a risk of long-term complications, Nexsphere-F™ is designed to dissolve and be naturally absorbed by the body within 2 to 8 hours after the procedure. This rapid resorption significantly reduces the risk of post-procedural issues, addressing a key concern among interventional radiologists and their patients.

The clinical advantages of this approach have been highlighted in major medical forums. At the 2025 annual congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), Dr. Florian Nima Fleckenstein of Charité-Universitätsmedizin Berlin presented compelling findings. His research showed that using Nexsphere-F™ for knee osteoarthritis pain embolization led to "significant improvements in pain and function, while demonstrating favorable safety compared to permanent microspheres or antibiotic-based compounds."

A Strategic Gateway to North America

While the Health Canada approval is a major victory in its own right, it is also a crucial component of NEXTBIOMEDICAL's broader global strategy, particularly its focus on the lucrative North American market. This regulatory milestone provides validation and a commercial foothold as the company pursues an even larger prize: approval from the U.S. Food and Drug Administration (FDA).

NEXTBIOMEDICAL is already well on its way in the United States. The company has received an Investigational Device Exemption (IDE) from the FDA to conduct a pivotal clinical trial named RESORB. This multicenter, randomized controlled study is actively enrolling 126 patients with knee osteoarthritis across more than 10 leading U.S. clinical sites. The trial is designed to rigorously evaluate the safety and efficacy of genicular artery embolization (GAE) using Nexsphere-F™ against the current standard of care, intra-articular corticosteroid injections.

Further accelerating its U.S. ambitions, Nexsphere-F™ was granted a Breakthrough Device Designation by the FDA in March 2025. This program is designed to expedite the development and review of medical devices that offer more effective treatment for life-threatening or irreversibly debilitating diseases. The designation, coupled with the company’s participation in the FDA's Total Product Lifecycle Advisory Program (TAP), signals strong regulatory confidence in the device's potential. Patient enrollment for the RESORB trial is expected to be completed within the first half of this year.

Beyond Knee Osteoarthritis: A Versatile Platform

The potential applications for Nexsphere-F™ extend far beyond knee pain. While osteoarthritis is a primary target—affecting over 650 million people worldwide and representing a significant unmet medical need—NEXTBIOMEDICAL is actively demonstrating the technology's versatility across a spectrum of musculoskeletal conditions.

A study published in the prestigious Orthopaedic Journal of Sports Medicine has already underscored the clinical efficacy and safety of Nexsphere-F™ for treating patellar tendinopathy, a common and painful overuse injury often seen in athletes. This success has prompted further investigation into other chronic pain sources.

The company is sponsoring multiple post-market clinical trials in several countries to build a robust evidence base for a wide range of indications. These include conditions that plague millions, such as medial epicondylitis (golfer's elbow), plantar fasciitis (a leading cause of heel pain), and other chronic pain syndromes affecting the elbow, wrist, and other joints. This broad research effort aims to establish Nexsphere-F™ as a comprehensive platform solution for interventional pain management.

With European commercialization already underway—backed by a CE-MDD certification for osteoarthritis pain embolization—and strong sales growth reported in 2025, NEXTBIOMEDICAL is building formidable global momentum. The company has confirmed it is in active discussions with leading global partners for distribution rights. As clinical evidence mounts and regulatory approvals accumulate, this resorbable microsphere technology is poised to redefine the standard of care for patients seeking lasting relief from chronic musculoskeletal pain.